(Reuters) -Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesCompany aims to accelerate access to much-needed biosimilar to reference ...

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for ...

Shares of Amgen Inc. AMGN rose 1.62% to $285.98 Friday, on what proved to be an all-around great trading session for the ...

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

Big Pharma and biotech startups alike are counting on AI to speed the process of drug discovery and make their operations ...

Amgen (AMGN) announced that the global Phase 3 DeLLphi-304 clinical trial evaluating Imdelltra as a treatment for patients with small cell lung ...

The bispecific antibody helped people with small cell lung cancer live longer, Amgen said. Elsewhere, J&J shared new ...

Federated Hermes Inc. gave Amgen a major dose of investment confidence, upping its stake by nearly 40% in the fourth quarter.

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Despite resilient demand, healthcare has taken a hit along with the rest of the market. Amgen could boost profits ...

Inebilizumab, a first-in-class CD19+ B-cell–targeting agent, is safe and effective for up to 1 year in patients with generalized myasthenia gravis, a phase 3 trial suggests.